T1	Participants 96 143	patients with advanced-stage Hodgkin's lymphoma
T2	Participants 180 217	German Hodgkin's Lymphoma Study Group
T3	Participants 731 781	The randomized, three-arm trial recruited patients
T4	Participants 1294 1342	An interim analysis with 505 assessable patients
T5	Participants 2018 2104	BEACOPP in one or both variants shows superior disease control compared with COPP/ABVD
